Meeting
2020 Genitourinary Cancers Symposium
The prevalence of cardiovascular disease and its risk factors among prostate cancer patients treated with and without androgen deprivation.
Authors
Jehonathan H. Pinthus
McMaster University, Hamilton, ON, Canada
Jehonathan H. Pinthus , Bobby Shayegan , Laurence Klotz , D. Robert Siemens , Patrick P. Luke , Tamim Niazi , Vincent Fradet , Yves Fradet , Emmanuelle Duceppe , Luke Lavallee , Negareh Mousavi , Robert James Hamilton , Ian Brown , Joseph Chin , Darin Gopaul , Philippe Violette , Margot Davis , Rajibul Mian , Sarah Karampatos , Darryl Leong
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers
Track
Urothelial Carcinoma,Adrenal Cancer,Penile Cancer,Prostate Cancer - Advanced,Prostate Cancer - Localized,Testicular Cancer,Urethral Cancer
Sub Track
Symptoms, Toxicities, and Whole-Person Care
Clinical Trial Registration Number
NCT03127631
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 364)
Abstract #
364
Poster Bd #
C16
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
A novel cardiovascular disease risk score for prediction of atherosclerotic disease events in men with prostate cancer.
First Author: Nickolas Stabellini
First Author: Jehonathan H Pinthus
Poster
2024 ASCO Genitourinary Cancers Symposium
Racial and ethnic differences in the receipt of metabolic syndrome risk factor screening and treatment among individuals with prostate cancer treated with androgen deprivation therapy.
First Author: Yazan K. Barqawi
Poster
2023 ASCO Annual Meeting
Exercise to enhance cardiovascular health among Black patients with prostate cancer with androgen deprivation therapy: The POWER trial.
First Author: Dong-Woo Kang